Literature DB >> 23741249

RhoA regulates invasion of glioma cells via the c-Jun NH2-terminal kinase pathway under hypoxia.

Jiao Jian Tong1, Zhang Yan, Ren Jian, Huang Tao, Ouyang Tao Hui, Chen Jian.   

Abstract

The purpose of this study was to investigate the mechanism of glioma cell invasion in hypoxic conditions. We demonstrated that hypoxia increased cell invasion, matrix metalloproteinase-2 (MMP2) activity and time-dependent expression of hypoxia inducible factor-1α (HIF-1α) in human glioma cells. These data suggest that MMP2 may play a significant role in tumor invasion in hypoxic conditions. We investigated the mechanisms involved in the increased MMP2 activity and cell invasion in hypoxic conditions. Increased expression of phospho-Jun NH2-terminal kinase (p-JNK) and phospho-c-Jun (p-c-Jun) in glioma cells induced by hypoxia was detected. Furthermore, this effect may be reduced by inhibiting the JNK signaling pathway. We found that inhibition of RhoA geranylgeranylation by geranylgeranyltransferase inhibitor-2147 (GGTI-2147) or knockdown of RhoA by siRNA against RhoA reduced the expression of p-JNK and p-c-Jun, and decreased MMP2 activity and glioma cell invasion in hypoxic conditions. These data suggest a link among RhoA, JNK, c-Jun and MMP2 activity that is functionally involved in the increased glioma cell invasion induced by hypoxia.

Entities:  

Keywords:  RhoA-JNK signaling pathway; U251 cell line; cell invasion; glioma; hypoxia; matrix metalloproteinase-2

Year:  2012        PMID: 23741249      PMCID: PMC3673639          DOI: 10.3892/ol.2012.777

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.

Authors:  A Vogt; J Sun; Y Qian; A D Hamilton; S M Sebti
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

2.  Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho.

Authors:  Kenjiro Sawada; Ken-Ichirou Morishige; Masahiro Tahara; Rikako Kawagishi; Yoshihide Ikebuchi; Keiichi Tasaka; Yuji Murata
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

3.  Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.

Authors:  C Denoyelle; M Vasse; M Körner; Z Mishal; F Ganné; J P Vannier; J Soria; C Soria
Journal:  Carcinogenesis       Date:  2001-08       Impact factor: 4.944

Review 4.  General mechanisms of metastasis.

Authors:  E C Woodhouse; R F Chuaqui; L A Liotta
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 5.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.

Authors:  Matthijs R Graaf; Dick J Richel; Cornelis J F van Noorden; Henk-Jan Guchelaar
Journal:  Cancer Treat Rev       Date:  2004-11       Impact factor: 12.111

6.  Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas.

Authors:  S Loeper; B F Romeike; N Heckmann; V Jung; W Henn; W Feiden; K D Zang; S Urbschat
Journal:  Cytogenet Cell Genet       Date:  2001

7.  Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.

Authors:  Gheeyoung Choe; Jun K Park; Lisa Jouben-Steele; Thomas J Kremen; Linda M Liau; Harry V Vinters; Timothy F Cloughesy; Paul S Mischel
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

Review 8.  Hypoxia-driven selection of the metastatic phenotype.

Authors:  Richard Sullivan; Charles H Graham
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

9.  Activation of cAMP and mitogen responsive genes relies on a common nuclear factor.

Authors:  J Arias; A S Alberts; P Brindle; F X Claret; T Smeal; M Karin; J Feramisco; M Montminy
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

10.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  4 in total

1.  ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.

Authors:  Susobhan Sarkar; Franz J Zemp; Donna Senger; Stephen M Robbins; V Wee Yong
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

2.  RalA is overactivated in medulloblastoma.

Authors:  Kevin F Ginn; Ben Fangman; Kaoru Terai; Amanda Wise; Daniel Ziazadeh; Kushal Shah; Robyn Gartrell; Brandon Ricke; Kyle Kimura; Sharad Mathur; Emma Borrego-Diaz; Faris Farassati
Journal:  J Neurooncol       Date:  2016-08-26       Impact factor: 4.130

Review 3.  Pyruvate dehydrogenase kinase as a potential therapeutic target for malignant gliomas.

Authors:  Mithilesh Kumar Jha; Kyoungho Suk
Journal:  Brain Tumor Res Treat       Date:  2013-10-31

4.  Silencing of the tumor suppressor gene WNK2 is associated with upregulation of MMP2 and JNK in gliomas.

Authors:  Angela Margarida Costa; Filipe Pinto; Olga Martinho; Maria José Oliveira; Peter Jordan; Rui Manuel Reis
Journal:  Oncotarget       Date:  2015-01-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.